Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18810577 | MICROMOLECULAR TYPE III COLLAGEN PEPTIDE CAPABLE OF PROMOTING SECRETION OF TYPE III AND IV COLLAGENS, AND PREPARATION METHOD THEREFOR | August 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18488299 | DNA REPAIR COMPOSITION | October 2023 | November 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18481086 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18340802 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | June 2023 | September 2024 | Allow | 15 | 1 | 1 | No | No |
| 18334449 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18334034 | APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18333904 | INDUCIBLE CASPASES AND METHODS FOR USE | June 2023 | March 2025 | Allow | 21 | 1 | 0 | No | No |
| 18298742 | METHODS OF PURIFYING RECOMBINANT ADAMTS13 AND OTHER PROTEINS AND COMPOSITIONS THEREOF | April 2023 | August 2025 | Allow | 28 | 1 | 1 | No | No |
| 18191395 | COMPOSITIONS COMPRISING DIGESTIVE ENZYMES | March 2023 | April 2025 | Allow | 25 | 1 | 0 | No | No |
| 18189091 | PENICILLIN-G ACYLASES | March 2023 | July 2025 | Allow | 28 | 1 | 1 | No | No |
| 18167534 | MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE | February 2023 | February 2025 | Allow | 24 | 0 | 1 | No | No |
| 18040497 | DEER-DERIVED SPECIFIC PEPTIDE AND DETECTION METHOD THEREFOR | February 2023 | November 2024 | Allow | 22 | 1 | 0 | No | No |
| 18160144 | GLYCAN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | January 2023 | March 2025 | Allow | 26 | 1 | 0 | No | No |
| 18153576 | DESIGNED ANKYRIN REPEAT DOMAINS WITH ALTERED SURFACE RESIDUES | January 2023 | June 2025 | Allow | 29 | 2 | 0 | No | No |
| 18083598 | High-Strength Collagen Sponge | December 2022 | March 2025 | Allow | 27 | 2 | 0 | No | No |
| 18063578 | MULTIPLE RAPID DETECTION KITS AND METHODS FOR VARIOUS VIRUSES | December 2022 | June 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18060292 | FUSOGENIC LIPID NANOPARTICLES FOR TARGET CELL-SPECIFIC PRODUCTION OF A THERAPEUTIC PROTEIN FUSOGENIC LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF FOR THE TARGET CELL-SPECIFIC PRODUCTION OF A THERAPEUTIC PROTEIN AND FOR THE TREATMENT OF A DISEASE | November 2022 | April 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18059308 | CYTOSINE TO GUANINE BASE EDITOR | November 2022 | June 2025 | Allow | 30 | 2 | 0 | Yes | No |
| 18056752 | METHODS AND PRODUCTS FOR IN VIVO ENZYME PROFILING | November 2022 | April 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18050666 | URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF | October 2022 | November 2023 | Allow | 13 | 1 | 1 | No | No |
| 17936072 | PRODUCTION OF GUAIENE AND ROTUNDONE | September 2022 | July 2025 | Allow | 34 | 1 | 1 | No | No |
| 17933943 | Compositions and Methods for Detecting Molecular Targets on Chromosomal DNA | September 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17822175 | LACTOFERRIN COMPOSITIONS AND METHODS FOR MODULATION OF T CELL SUBTYPES AND TREATMENT OF AUTOIMMUNE DISEASES | August 2022 | July 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17812875 | COMPOSITIONS AND METHODS FOR SUCCINATE PRODUCTION | July 2022 | June 2025 | Allow | 35 | 2 | 0 | No | No |
| 17810985 | C-PEPTIDES AND PROINSULIN POLYPEPTIDES COMPRISING THE SAME | July 2022 | July 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17856863 | CO-PRODUCTION PATHWAY FOR 3-HPA AND ACETYL-COA DERIVATIVES FROM MALONATE SEMIALDEHYDE | July 2022 | April 2025 | Allow | 33 | 1 | 1 | No | No |
| 17830822 | RNA-BINDING PROTEIN | June 2022 | March 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17830773 | INDUCIBLE CASPASES AND METHODS FOR USE | June 2022 | March 2023 | Allow | 9 | 0 | 0 | No | No |
| 17750833 | IN VIVO ENGINEERED CEREBLON PROTEIN | May 2022 | November 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17712155 | NOVEL EXOSOME-BASED ANTICANCER AGENT | April 2022 | December 2023 | Allow | 20 | 2 | 1 | Yes | No |
| 17656728 | ALBUMIN VARIANTS AND CONJUGATES | March 2022 | May 2024 | Allow | 26 | 1 | 1 | No | No |
| 17700548 | GENE ANSB KNOCKOUT MUTANT OF CITROBACTER WERKMANII AND APPLICATION THEREOF | March 2022 | November 2022 | Allow | 8 | 1 | 0 | No | No |
| 17700461 | COMPOSITIONS AND METHODS FOR TREATING CONTAMINATED WATER | March 2022 | June 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17669844 | TREATMENT OF ISCHEMIA | February 2022 | August 2023 | Allow | 18 | 2 | 0 | No | No |
| 17650577 | SYSTEMS AND METHODS FOR MANUFACTURING A SILK FIBROIN SOLUTION AND POWDERS CONTAINING SILK FIBROIN | February 2022 | October 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17668674 | ENGINEERING OF DNASE ENZYMES FOR MANUFACTURING AND THERAPY | February 2022 | October 2022 | Allow | 8 | 1 | 0 | No | No |
| 17592915 | METHODS FOR REGULATING NITROGEN METABOLISM DURING THE PRODUCTION OF ETHANOL FROM CORN BY METABOLICALLY ENGINEERED YEAST STRAINS | February 2022 | November 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17570847 | METHODS AND PRODUCTS FOR IN VIVO ENZYME PROFILING | January 2022 | August 2022 | Allow | 7 | 2 | 0 | No | No |
| 17622318 | METHODS FOR PREPARATION OF ACTIVE SEPARASE | December 2021 | November 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17537941 | PENICILLIN-G ACYLASES | November 2021 | December 2023 | Allow | 25 | 2 | 0 | No | No |
| 17456126 | METHODS FOR PRODUCTION OF OXYGENATED TERPENES | November 2021 | June 2023 | Allow | 19 | 1 | 1 | No | No |
| 17529138 | COMPOSITIONS, FORMULATIONS AND INTERLEUKIN PRODUCTION AND PURIFICATION | November 2021 | May 2022 | Allow | 6 | 1 | 0 | No | No |
| 17528029 | COMPOSITIONS AND METHODS FOR MODIFYING HAIR COLOR | November 2021 | August 2024 | Allow | 33 | 4 | 0 | Yes | No |
| 17527006 | COMPOSITIONS AND METHODS FOR ENHANCING THE PLURIPOTENCY OF STEM CELLS | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17525097 | Carrier Peptide Fragment and Use Thereof | November 2021 | September 2023 | Allow | 22 | 1 | 0 | No | No |
| 17522216 | Virus Filtration of Liquid Factor VII Compositions | November 2021 | September 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17519029 | SMART SINGLE-DOMAIN INTRABODIES WITH PRECISION SWITCHES FOR BIOMEDICAL APPLICATIONS | November 2021 | July 2024 | Allow | 32 | 1 | 1 | No | No |
| 17452995 | COMPOSITION AND METHODS FOR PREVENTING OR REDUCING THE INCIDENCE OF TRANSIENT ISCHEMIC ATTACKS | October 2021 | August 2023 | Allow | 22 | 2 | 0 | No | No |
| 17603864 | A NITRILASE MUTANT AND APPLICATION THEREOF IN THE SYNTHESIS OF 1-CYANOCYCLOHEXYL ACETIC ACID | October 2021 | June 2025 | Allow | 44 | 2 | 0 | No | No |
| 17497484 | PROCESS FOR PREPARING SPHINGOLIPIDS | October 2021 | January 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17600960 | FUNCTIONALIZED UBX PROTEIN MATERIALS FOR ENHANCED PURIFICATION OF ANTIBODIES | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17484610 | NON-ANTIBODY HIGH-AFFINITY-BASED SAMPLE PREPARATION, SORBENT, DEVICES AND METHODS | September 2021 | May 2024 | Allow | 32 | 3 | 0 | No | No |
| 17441902 | FUNCTIONALIZED GLASS BEADS, USE THEREOF FOR CAPTURING MICROORGANISMS, AND CORRESPONDING DEVICES | September 2021 | February 2025 | Allow | 41 | 1 | 1 | No | No |
| 17478277 | POLYPEPTIDES HAVING RNASE ACTIVITY | September 2021 | September 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17470055 | INSECT TOXIN DELIVERY MEDIATED BY A DENSOVIRUS COAT PROTEIN | September 2021 | October 2023 | Allow | 26 | 1 | 1 | No | No |
| 17467601 | COMPOSITIONS COMPRISING DIGESTIVE ENZYMES | September 2021 | March 2023 | Allow | 18 | 1 | 1 | No | No |
| 17466239 | CONCENTRATED AQUEOUS SILK FIBROIN SOLUTION AND USE THEREOF | September 2021 | November 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17408306 | CAS VARIANTS FOR GENE EDITING | August 2021 | August 2024 | Allow | 36 | 2 | 0 | No | Yes |
| 17402222 | Dynamic Bio-Nanoparticle Platforms | August 2021 | October 2024 | Allow | 38 | 3 | 1 | No | No |
| 17400471 | DESIGNED ANKYRIN REPEAT DOMAINS WITH ALTERED SURFACE RESIDUES | August 2021 | April 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17393575 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | August 2021 | September 2024 | Allow | 37 | 3 | 0 | No | No |
| 17383373 | SYSTEMS AND PROCESSES FOR OBTAINING NATURAL PRESERVATIVES AND NUTRITIONAL SUPPLEMENTS | July 2021 | October 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17413333 | OPTIMIZED PROCESS FOR DIMERIC PEPTIDE-PHOSPHOLIPID CONJUGATE | June 2021 | May 2022 | Allow | 11 | 0 | 0 | No | No |
| 17342216 | Compositions and Methods for Detecting Molecular Targets on Chromosomal DNA | June 2021 | September 2022 | Allow | 16 | 2 | 1 | Yes | No |
| 17332208 | ALKALINE PHOSPHATASE FUSION ANTIBODY AND METHOD FOR PRODUCING THE SAME, AND IMMUNOASSAY METHOD | May 2021 | July 2023 | Allow | 26 | 2 | 0 | Yes | No |
| 17330686 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | May 2021 | January 2024 | Allow | 32 | 2 | 1 | No | No |
| 17320471 | AUXOTROPHIC STRAINS OF STAPHYLOCOCCUS BACTERIUM | May 2021 | April 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17308921 | APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER | May 2021 | March 2023 | Allow | 22 | 1 | 0 | No | No |
| 17242973 | METHOD FOR AUTOMATED PROTEIN PURIFICATION | April 2021 | March 2025 | Allow | 46 | 2 | 1 | No | No |
| 17232470 | N-TERMINAL CAPPING MODULES OF ANKYRIN REPEAT DOMAINS | April 2021 | July 2021 | Allow | 3 | 1 | 0 | Yes | No |
| 17284966 | A PEPTIDE, A COMPLEX AND A METHOD FOR TREATING CANCER | April 2021 | July 2025 | Allow | 51 | 2 | 1 | No | No |
| 17227598 | COMPOSITIONS AND METHODS FOR SUPPRESSING OR REDUCING SYSTEMIC IMMUNE RESPONSE IN A SUBJECT | April 2021 | May 2023 | Allow | 25 | 1 | 0 | No | No |
| 17225127 | PEARL CULTURE MATERIAL, NUCLEUS INSERTION METHOD, AND PEARL CULTURE MATERIAL COMPOSITION | April 2021 | August 2022 | Allow | 16 | 3 | 1 | Yes | No |
| 17225551 | PROCESS FOR ENZYMATIC HYDROLYSIS OF LIGNOCELLULOSIC MATERIAL AND FERMENTATION OF SUGARS | April 2021 | May 2023 | Allow | 26 | 2 | 0 | No | No |
| 17219277 | Elastomeric Proteins | March 2021 | August 2023 | Allow | 28 | 2 | 0 | No | No |
| 17196151 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | March 2021 | June 2023 | Allow | 28 | 1 | 1 | No | No |
| 17190173 | COMPOSITIONS COMPRISING DIGESTIVE ENZYMES | March 2021 | July 2021 | Allow | 4 | 0 | 1 | No | No |
| 17187502 | SOLUBLE ACE2 VARIANTS AND USES THEREFOR | February 2021 | July 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17270044 | IMMOBILIZED ENZYMES AND MICROSOMES ON MAGNETIC SCAFFOLDS | February 2021 | September 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17248952 | COMPOSITION FOR REDUCING NERVOUS SYSTEM INJURY AND METHOD OF MAKING AND USE THEREOF | February 2021 | October 2022 | Allow | 20 | 0 | 0 | No | No |
| 17266580 | METHOD FOR PRODUCING ACTIVE FORM OF LONG-ACTING INSULIN ANALOGUE DERIVATIVE USING CLOSTRIPAIN | February 2021 | March 2023 | Allow | 25 | 1 | 0 | No | No |
| 17169396 | COMPOSITIONS, FORMULATIONS AND INTERLEUKIN PRODUCTION AND PURIFICATION | February 2021 | August 2021 | Allow | 6 | 1 | 1 | Yes | No |
| 17154610 | FORMATION OF STABLE SUBMICRON PEPTIDE OR PROTEIN PARTICLES BY THIN FILM FREEZING | January 2021 | April 2023 | Allow | 27 | 1 | 0 | No | No |
| 17150210 | SYSTEMS AND METHODS FOR MANUFACTURE OF ENDOTOXIN-FREE HEMOGLOBIN-BASED DRUG SUBSTANCE | January 2021 | July 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17126942 | TEMPERATURE-SENSITIVE CELL CULTURE COMPOSITION, METHOD FOR USING THE SAME, METHOD FOR FORMING THE SAME, AND USE THEREOF | December 2020 | October 2024 | Allow | 46 | 2 | 1 | No | No |
| 17118814 | ENZYME-POROUS CARBON COMPOSITE | December 2020 | October 2021 | Allow | 10 | 2 | 0 | Yes | No |
| 16973625 | COMPOSITION FOR CELL TRANSPLANT, AND METHOD FOR CELL TRANSPLANT | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17112020 | Drug Carrier, Brain-targeting Nanodrug Based on CRISPR Gene Editing Technology and Preparation Method and Use thereof | December 2020 | August 2024 | Allow | 45 | 2 | 1 | No | No |
| 17107468 | SYSTEM AND METHOD FOR MICRONEEDLE DELIVERY OF MICROENCAPSULATED VACCINE AND BIOACTIVE PROTEINS | November 2020 | February 2023 | Allow | 27 | 1 | 0 | No | No |
| 17091075 | METHODS AND PRODUCTS FOR IN VIVO ENZYME PROFILING | November 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17087294 | GASTROINTESTINAL TRACT THERAPEUTIC AGENTS | November 2020 | September 2024 | Abandon | 46 | 3 | 0 | No | No |
| 17078319 | De Novo Designed Non-Local Beta Sheet Proteins | October 2020 | June 2023 | Allow | 32 | 1 | 1 | No | No |
| 17073439 | SYNTHESIS OF GLUCAN COMPRISING ALPHA-1,3 GLYCOSIDIC LINKAGES WITH PHOSPHORYLASE ENZYMES | October 2020 | June 2022 | Allow | 20 | 0 | 0 | No | No |
| 17071341 | PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME | October 2020 | December 2022 | Abandon | 26 | 0 | 1 | No | No |
| 17034858 | ORAL DISSOLVING FILMS CONTAINING MICROENCAPSULATED VACCINES AND METHODS OF MAKING SAME | September 2020 | September 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 17042682 | PEPTIDES AND CONJUGATES | September 2020 | September 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 17041363 | BETA BARREL POLYPEPTIDES AND METHODS FOR THEIR USE | September 2020 | May 2024 | Allow | 43 | 1 | 1 | No | No |
| 17021130 | METHOD OF DECELLULARIZATION OF KIDNEY TISSUES, DECELLULARIZED MATERIAL BY THE METHOD AND BIOINK COMPRISING THE DECELLULARIZED MATERIAL | September 2020 | May 2023 | Allow | 32 | 1 | 1 | No | No |
| 16980027 | METHOD FOR DETERMINING THE ANTIOXIDANT CAPACITY OF A BIOLOGICAL SAMPLE AND RELATED KIT | September 2020 | June 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16980178 | MICROPEPTIDES AND USES THEREOF | September 2020 | September 2023 | Allow | 36 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DESAI, ANAND U.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DESAI, ANAND U works in Art Unit 1656 and has examined 804 patent applications in our dataset. With an allowance rate of 66.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner DESAI, ANAND U's allowance rate of 66.0% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DESAI, ANAND U receive 1.58 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by DESAI, ANAND U is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +25.7% benefit to allowance rate for applications examined by DESAI, ANAND U. This interview benefit is in the 72% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 29.1% of applications are subsequently allowed. This success rate is in the 54% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 56.9% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 89.3% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 76.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 62.8% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 5.5% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.